Evidence map›Paper›PMID 39884393›Full record

ArticleMucosal immunology2025

Damage sensing through TLR9 regulates inflammatory and antiviral responses during influenza infection.

Jooyoung Kim, Yifan Yuan, Karen Agaronyan, Amy Zhao, Victoria D Wang, David Gau, Nicholas Toosi, Gayatri Gupta, Heran Essayas, Ayelet Kaminski and 18 more

Abstract read
In one paragraph

Article in Mucosal immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jooyoung KimDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA; Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Yifan YuanSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA; University of Maryland MD USA.
Karen AgaronyanSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA; Howard Hughes Medical Institute, USA.
Amy ZhaoSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Victoria D WangDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA.
David GauDepartment of Pathology, University of Pittsburgh Pittsburgh PA USA; Department of Bioengineering, University of Pittsburgh Pittsburgh PA USA.
Nicholas ToosiDepartment of Bioengineering, University of Pittsburgh Pittsburgh PA USA.
Gayatri GuptaSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Heran EssayasSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Ayelet KaminskiSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
John McGovernSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Sheeline YuSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Samuel WooSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Chris J LeeSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Shifa GandhiSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Tina SaberSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Tayebeh SalehDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA.
Buqu HuSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Ying SunSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Genta IshikawaSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
William BainDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA; VA Medical Center Pittsburgh PA USA.
John EvankovichDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA.
Lujia ChenDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA.
HongDuck YunDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA.
Erica L HerzogSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA.
Charles S Dela CruzDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA; Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA; VA Medical Center Pittsburgh PA USA.
Changwan RyuSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA. Electronic address: changwan.ryu@yale.edu.
Lokesh SharmaDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh Medical Center Pittsburgh PA USA; Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine New Haven CT USA. Electronic address: sharmalk2@upmc.edu.

Funding

Noradrenergic mechanisms of IPFR01HL163984 · NHLBI · YALE UNIVERSITY · PI Erica L Herzog · 2022 to 2026
$3.7M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
Macrophage driven, profibrotic adrenergic nerve remodeling in SSc-ILDR01HL152677 · NHLBI · YALE UNIVERSITY · PI HERZOG, ERICA L · 2020 to 2023
$2.4M
Mitochondrial DNA and TLR9 in Pulmonary FibrosisK08HL151970 · NHLBI · YALE UNIVERSITY · PI RYU, CHANGWAN · 2020 to 2024
$840k
Profilin as a Novel Target for Vascular Normalization in Renal CancerR00CA267180 · NCI · UNIVERSITY OF TEXAS DALLAS · PI David Martin Gau · 2024 to 2026
$747k
Reconstructing native soluble cues in vascularized whole lung scaffoldsR00HL159261 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI YUAN, YIFAN · 2023 to 2025
$747k
Reconstructing native soluble cues in vascularized whole lung scaffoldsK99HL159261 · NHLBI · YALE UNIVERSITY · PI YUAN, YIFAN · 2022 to 2023
$245k
NCI NIH HHS R00 CA267180NHLBI NIH HHS K08 HL151970NHLBI NIH HHS K99 HL159261NHLBI NIH HHS R00 HL159261NHLBI NIH HHS R01 HL152677NHLBI NIH HHS R01 HL163984NIAID NIH HHS R25 AI147376
6 · The paper itself

Abstract

Host response aimed at eliminating the infecting pathogen, as well as the pathogen itself, can cause tissue injury. Tissue injury leads to the release of a myriad of cellular components including mitochondrial DNA (mtDNA), which the host senses through pattern recognition receptors. How the sensing of tissue injury by the host shapes the anti-pathogen response remains poorly understood. In this study, we utilized mice that are deficient in toll-like receptor-9 (TLR9), which binds to unmethylated CpG DNA sequences such as those present in bacterial and mtDNA. To avoid direct pathogen sensing by TLR9, we utilized the influenza virus, which lacks ligands for TLR9, to determine how damage sensing by TLR9 contributes to anti-influenza immunity. Our data showed that TLR9-mediated sensing of tissue damage promoted an inflammatory response during early infection, driven by epithelial and myeloid cells. Along with the diminished inflammatory response, the absence of TLR9 led to impaired viral clearance manifested as higher and prolonged influenza components in myeloid cells, including monocytes and macrophages, rendering them highly inflammatory. The persistent inflammation driven by infected myeloid cells led to persistent lung injury and impaired recovery in influenza-infected TLR9-/- mice. Further, we found elevated TLR9 ligands in the plasma samples of patients with influenza infection and its association with the disease severity in hospitalized patients, demonstrating its clinical relevance. Overall, we demonstrated an essential role of damage sensing through TLR9 in promoting anti-influenza immunity and inflammatory response. AUTHOR SUMMARY: Tissue damage is an inevitable outcome of clinically relevant lung infections, but the host mechanisms for detecting such damage during infection are not well understood. We investigated the role of Toll-like receptor 9 (TLR9) in sensing tissue damage caused by influenza. Since influenza lacks TLR9 ligands, we hypothesized that TLR9 signaling is driven by tissue damage molecules like mitochondrial DNA (mtDNA). Our data revealed that TLR9 deficiency reduces early inflammatory lung injury but impairs viral clearance, resulting in extensive infection of immune cells, persistent inflammation, and delayed recovery. Myeloid-specific TLR9 deletion ameliorated late-stage inflammatory responses. In humans, influenza-infected individuals exhibited elevated TLR9 activity and mtDNA levels in plasma compared to healthy controls, with higher TLR9 activation potential correlating with severe disease requiring ICU admission. These findings suggest that TLR9-mediated damage sensing triggers both inflammatory tissue injury and viral clearance. These data indicate that TLR9 activity can serve as a crucial biomarker and therapeutic target to limit influenza-induced tissue injury.

Indexed as

InflammationInfluenza, HumanOrthomyxoviridae InfectionsToll-Like Receptor 9AnimalsDisease Models, AnimalHumansMiceMice, Inbred C57BLMice, KnockoutMyeloid CellsSignal TransductionTLR9 protein, humanTlr9 protein, mouseToll-Like Receptor 9InflammationInfluenzaLung infectionTLR9

Identifiers

PMID39884393
PMCPMC12205908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.